Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age \>34 weeks~* postnatal age \<10 days~Exclusion Criteria:~* neonates with congenital heart disease~* neonates with congenital diaphragmatic hernia

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- milrinone (Type: ACTIVE_COMPARATOR): Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
- sildenafil (Type: ACTIVE_COMPARATOR): Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).